InvestorsHub Logo
icon url

StealthGold

11/24/21 10:28 AM

#194587 RE: B52T38 #194586

Just compare the last two PRs regarding NASH. The first had 5 initial patients and this one has 15. The fat reduction is still "up to 45%" - this means the additional 10 patients did not see higher than the 45% from the first 5.
The fibrosis reduction in the first 5 was PRed at "up to 10%". Now with 15 they say "up to 8%". So judge for yourself, what is really this PR about?

Simple - NOTHING that would move the needle. This is just NP talking because he has a hole in his face. Let's see the vote result.
icon url

justdafactss

11/24/21 10:28 AM

#194589 RE: B52T38 #194586

Last nights 8K wreaks of desperation for cash especially on the eve of the annual meeting.
https://www.sec.gov/Archives/edgar/data/1175680/000119312521338644/d173754d8k.htm

NASH and NALFD? LOL, CYDY is in trouble.
icon url

jimmy667

11/24/21 11:35 AM

#194615 RE: B52T38 #194586

Currently there is no TREATMENT AT ALL FOR NASH other than LIVER TRANSPLANT. SO NO SOC hence Accerated approval. Arrowhead made a 1 billion partnership agreement for ARWR early clinical stage candidate.